Interferon γ Expressing Mucosal Cells in Pediatric Chronic Inflammatory Bowel Disease

Jefferson Terry1

  • 1Department of Pathology, British Columbia Children's and Women's Hospitals, Vancouver, BC, Canada.

Insights

Interferon gamma (IFNγ) levels in the gut lining may help distinguish Crohn's disease (CD) from ulcerative colitis (UC). Increased IFNγ was observed in CD ileum and in the colon for both conditions, but overlap limits its diagnostic use.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pathology

Background:

  • Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases with distinct treatments and prognoses.
  • Differentiating CD and UC can be challenging due to overlapping clinical and histological features.
  • Aberrations in gastrointestinal mucosal inflammatory cells are implicated in CD and UC pathogenesis.

Purpose of the Study:

  • To investigate the diagnostic utility of Interferon gamma (IFNγ) immunohistochemical expression in differentiating pediatric CD and UC.
  • To assess IFNγ expression in various gastrointestinal mucosal sites (stomach, duodenum, terminal ileum, colon).

Main Methods:

  • Automated assessment of IFNγ-positive mucosal cells in archival GI biopsies from a pediatric cohort.
  • Comparison of IFNγ expression between CD, UC, and normal controls across different gastrointestinal segments.

Main Results:

  • IFNγ-positive cells were elevated in the colon of both CD and UC patients compared to controls.
  • IFNγ-positive cells were increased in the ileum of CD patients compared to controls and UC patients.
  • IFNγ abundance did not correlate with active inflammation, suggesting it's an independent marker.

Conclusions:

  • IFNγ immunohistochemistry shows potential as a biomarker for differentiating CD and UC, particularly in the ileum.
  • Significant overlap in IFNγ expression between CD, UC, and normal tissues suggests limited clinical utility in routine diagnosis.
  • Further research is warranted to explore IFNγ's role in specific cases, such as indeterminate inflammatory bowel disease.

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
206
Renewal of Intestinal Stem Cells01:23

Renewal of Intestinal Stem Cells

The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124